Scholars Central

OtherPublished 23 Jul 2016

The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer

Authors: Saad A Khan, Julie E Bauman

Clinical Investigation

Volume 4 · Issue 12 · Pages 1123–113

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Phosphatidyl-inositol 3-kinase/Akt/mammalian target of rapamycin pathway (PI3K/ Akt/mTOR) is a critical signal transduction pathway in mammalian cellular biology, and is important to energy homeostasis, growth and survival. Activation of the pathway is an early event in head and neck squamous cell carcinoma (HNSCC) carcinogenesis. Moreover, PI3K/Akt/mTOR is the most commonly mutated pathway in HNSCC, with striking prevalence in human papillomavirus (HPV) associated disease. Genomic gain of function can also be conferred by PIK3CA gene amplification or loss of phosphatase and tensin homolog, the negative regulator of PI3K. Given the importance of PI3K/ Akt/mTOR signaling across the neoplastic spectrum, pathway inhibitors are of unique interest in HNSCC. This review will summarize current knowledge, highlight differences in HPV(+) and HPV(-) disease and discuss therapeutic agents in various phases of clinical development.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Saad A Khan”
  • BylineArticles whose byline prints “Julie E Bauman”